Step 1 topics → Microbiology → HIV Virology and Opportunistic Infections

HIV Virology and Opportunistic Infections

USMLE Step 1 trap: Confuses CCR5 and CXCR4 co-receptor tropism and their clinical significance in HIV infection stages. HIV uses CCR5 on macrophages (M-tropic, early infection) and CXCR4 on T cells (T-tropic, late infection); both require CD4 as the primary receptor.

HIV virology and opportunistic infections is one of the highest-yield topics on USMLE Step 1, appearing across virology, immunology, pharmacology, and clinical vignettes. The most commonly confused element is the NRTI drug-specific toxicity profile: abacavir causes potentially fatal hypersensitivity in HLA-B*5701 carriers; tenofovir causes nephrotoxicity and bone mineral density loss; zidovudine causes bone marrow suppression. The exam assigns one toxicity to a different drug deliberately — knowing all three by name is required. The CD4 threshold staircase (PCP prophylaxis at <200, toxoplasmosis at <100, MAC at <50) and the window-period diagnostic logic (HIV RNA PCR when antibody tests are falsely negative) are the other anchor concepts the exam tests at every format level.

What makes this topic trap students is the layered complexity — each component (virology, OIs, diagnosis, treatment) is individually testable, but the exam loves to combine them. A vignette might describe acute retroviral syndrome and ask about the best diagnostic test, testing whether you know antibody tests are unreliable in the window period. Or it might give a CD4 count of 75 and ask what prophylaxis is needed, expecting you to know that both PCP and toxoplasma thresholds have already been crossed. Students who memorize a single number or a single co-receptor name without understanding the context get burned.

The other major pitfall is conflating enzyme roles and drug mechanisms. A disturbingly common error on USMLE Step 1 is assigning integrase function to reverse transcriptase, or assuming all NRTIs have identical toxicity profiles. They don't — abacavir can kill a patient with the wrong HLA type, tenofovir destroys kidneys and bone, and zidovudine tanks bone marrow. The exam knows you'll default to 'class effect' and specifically tests whether you've learned the exceptions.

From real student decks
92%have cards covering this topic
62%have mature cards
1.0median lapses in 14 days

Common misconceptions

Common mistake
Wrong: HIV uses only CCR5 as its co-receptor for all cell types.
Right: HIV uses CCR5 on macrophages (M-tropic, early infection) and CXCR4 on T cells (T-tropic, late infection); both require CD4 as the primary receptor.
HIV always requires CD4 as its primary receptor — that part is constant. The co-receptor switches depending on the stage of infection and cell type: CCR5 is used early in infection to infect macrophages (M-tropic strains), while CXCR4 is used later to infect T cells (T-tropic strains). This matters clinically because CCR5 antagonists like maraviroc only work against CCR5-tropic virus, and individuals with the CCR5-delta32 mutation are relatively protected from infection — a classic Step 1 genetics hook.
Common mistake
Wrong: Reverse transcriptase integrates HIV DNA into the host genome.
Right: Reverse transcriptase converts viral RNA to dsDNA; integrase is the enzyme that inserts the viral dsDNA into the host chromosome.
These are two completely separate enzymes doing two completely separate jobs — keep them straight. Reverse transcriptase acts first: it takes the viral single-stranded RNA genome and converts it into double-stranded DNA. Integrase acts second: it takes that dsDNA and physically inserts it into the host cell's chromosome, creating the provirus. The drug classes reflect this split — NRTIs and NNRTIs inhibit reverse transcriptase, while integrase strand transfer inhibitors (like raltegravir) target integrase.
Common mistake
Wrong: PCP prophylaxis with TMP-SMX begins when CD4 drops below 200 and toxoplasma prophylaxis begins at the same threshold.
Right: PCP prophylaxis starts at CD4 <200; toxoplasma prophylaxis (also TMP-SMX) starts at CD4 <100; MAC prophylaxis (azithromycin) starts at CD4 <50.
Think of the CD4 thresholds as a staircase going down: at <200, start TMP-SMX for PCP prophylaxis; at <100, TMP-SMX also covers toxoplasma (same drug, lower threshold to remember); at <50, add azithromycin for MAC. The exam will give you a CD4 count and ask what you should start — if it's 75, the answer covers both PCP and toxoplasmosis. If it's 40, all three apply. Memorize the numbers and which drug covers which infection.
Common mistake
Wrong: A negative HIV antibody test rules out infection in a patient with acute retroviral syndrome.
Right: During acute HIV infection (window period), antibodies may be absent; HIV RNA PCR (viral load) is the most sensitive test for early/acute infection.
Antibodies take weeks to develop — during acute HIV infection (the 'window period'), the virus is replicating furiously but the immune system hasn't mounted a detectable antibody response yet. A patient presenting with fever, rash, lymphadenopathy, and pharyngitis two to four weeks after a high-risk exposure may have acute retroviral syndrome with a completely negative antibody test. HIV RNA PCR detects viral genome directly and is positive before antibodies appear, making it the correct test in this scenario. The current 4th-generation combo assay (p24 antigen + antibody) closes the window somewhat, but RNA PCR remains the most sensitive for very early infection.
Common mistake
Wrong: All NRTIs have the same toxicity profile.
Right: NRTIs have class-wide mitochondrial toxicity (lactic acidosis, lipodystrophy) but specific agents have unique toxicities: tenofovir causes nephrotoxicity/bone loss, zidovudine causes bone marrow suppression, abacavir causes hypersensitivity (HLA-B*5701).
All NRTIs share a class-wide toxicity from mitochondrial dysfunction — they inhibit mitochondrial DNA polymerase gamma, leading to lactic acidosis and lipodystrophy. But each agent also has a signature drug-specific toxicity that the exam tests directly: tenofovir causes nephrotoxicity (Fanconi syndrome) and decreased bone mineral density; zidovudine (AZT) causes bone marrow suppression, presenting as anemia or neutropenia; abacavir causes a potentially fatal hypersensitivity reaction in patients carrying the HLA-B*5701 allele — which is why patients are screened before starting it. Know the class effect and all three specific ones.
Common mistake
Gap: Misses the metabolic toxicity profile and boosting role of protease inhibitors
Protease inhibitors cause metabolic complications including hyperlipidemia, lipodystrophy, hyperglycemia/insulin resistance, and are associated with increased cardiovascular risk; ritonavir is used as a pharmacokinetic booster via CYP3A4 inhibition.
Protease inhibitors (PIs) block viral protease, preventing cleavage of polyprotein precursors into functional viral proteins. Their metabolic side effects are a major exam target: hyperlipidemia, central lipodystrophy (buffalo hump, truncal obesity), hyperglycemia, and insulin resistance — all together increasing cardiovascular risk. Ritonavir is the key PI to know pharmacologically: at low doses it's used not as an antiviral but as a pharmacokinetic booster, because it strongly inhibits CYP3A4 and raises plasma levels of co-administered PIs like lopinavir ('lopinavir/ritonavir'). The exam will test whether you know this boosting mechanism.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know HIV structure, the two co-receptors (CCR5 and CXCR4) and when each is used, and the distinct roles of reverse transcriptase, integrase, and protease in the HIV replication cycle.
  2. Given a patient's CD4 count, identify which opportunistic infections they are at risk for and which prophylactic agents should be started — PCP at <200, toxoplasma at <100, MAC at <50.
  3. Recognize when antibody testing is insufficient to diagnose HIV, and know that HIV RNA PCR (viral load) is the test of choice during acute infection or the window period.
  4. Identify the major HAART drug classes (NRTIs, NNRTIs, PIs, integrase inhibitors, fusion inhibitors), give examples of each, and distinguish class-wide toxicities from drug-specific ones — including the metabolic effects of protease inhibitors and the boosting role of ritonavir.

Can you avoid these mistakes?

A 28-year-old man presents with fever, pharyngitis, diffuse lymphadenopathy, and a maculopapular rash 3 weeks after unprotected sex. His HIV antibody test is negative. What is the most appropriate next test, and why would the antibody test be falsely negative at this stage?
You are managing a patient with HIV whose CD4 count just dropped to 80 cells/μL. Which opportunistic infections should you now provide prophylaxis against, and what drugs would you use for each?
A patient on HAART develops progressive proximal muscle weakness, elevated lactate, and hepatomegaly. Which drug class is most likely responsible, and what is the underlying mechanism of toxicity?
HIV binds CD4 on a macrophage — which co-receptor does it use, and how does this differ from the co-receptor used to infect T cells late in infection? What is the clinical significance of this difference for one specific antiretroviral drug?

Related topics

Bacterial Staining and Structure Bacterial Culture Requirements Encapsulated Organisms Bacterial Exotoxins

See how your Anki deck covers this topic.

Upload your deck for a free audit →